Tolerance of Anti-CMV Prophylaxis with Valganciclovir One-Year Treatment in D+/R- Lung Transplant Patients. A Single-Center Retrospective Study
| Autor: | François Parquin, L. Beaumont, S. Colin de Verdière, Anne-Françoise Roux, O. Brugière, A. Hamid, S. De Miranda, C. Roy, Clément Picard, Eric Farfour |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Pulmonary and Respiratory Medicine
Transplantation medicine.medical_specialty Lung Side effect business.industry Valganciclovir Retrospective cohort study Neutropenia Single Center medicine.disease medicine.anatomical_structure Internal medicine medicine Surgery Transplant patient Cardiology and Cardiovascular Medicine business Adverse effect medicine.drug |
| Zdroj: | The Journal of Heart and Lung Transplantation. 40:S340 |
| ISSN: | 1053-2498 |
| Popis: | Purpose Management of neutropenia, the main side effect of Valganciclovir, may affect final transplant results. The main objective of this study is to evaluate the safety of Valganciclovir in D+/R- patients. The secondary objectives are to assess the impact of neutropenia and Mycophenolate Mofetil (MMF) daily dosage modification on the outcomes of the transplant. Methods We performed a single-center retrospective study from 01/01/2010 to 12/31/2018 including 531 consecutive lung transplant patients. Results 59 of the 108 D+/R- patients (55%) experienced at least one episode of neutropenia during the first posttransplant year leading to its premature withdrawal for 31 patients (29%). Among D+/R- patients, subgroup of premature vGCV withdrawal experienced significantly more neutropenia and reduction of MMF in comparison with complete vGCV treatment subgroup (87% vs 42%, p Conclusion Considering adverse effects associated with Valganciclovir one-year treatment may have a negative impact on the outcomes of the transplant, an alternative should be proposed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|